R1 RCM RCM underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 6 | 2 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 1 | 3 | 1 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 1 | 2 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.05, a high estimate of $20.00, and a low estimate of $11.00. Highlighting a 13.45% decrease, the current average has fallen from the previous average price target of $19.70.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture of R1 RCM's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Stephanie Davis | Barclays | Announces | Overweight | $14.00 | - |
Craig Hettenbach | Morgan Stanley | Lowers | Overweight | $17.00 | $17.50 |
Anne Samuel | JP Morgan | Lowers | Neutral | $11.00 | $20.00 |
Sean Dodge | RBC Capital | Maintains | Outperform | $19.00 | - |
Richard Close | Canaccord Genuity | Maintains | Buy | $17.00 | - |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $20.00 | - |
Sean Dodge | RBC Capital | Lowers | Outperform | $19.00 | $22.00 |
Craig Hettenbach | Morgan Stanley | Lowers | Equal-Weight | $17.50 | $19.00 |
Scott Schoenhaus | Keybanc | Lowers | Overweight | $18.00 | $20.00 |
Jailendra Singh | Truist Securities | Announces | Buy | $18.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to R1 RCM. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of R1 RCM compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for R1 RCM's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of R1 RCM's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on R1 RCM analyst ratings.
Discovering R1 RCM: A Closer Look
R1 RCM Inc is a provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Its services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for the customers, Its service offering consists of end-to-end RCM services for health systems, hospitals, and physician groups that provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. The majority of the revenue comes from the operating fees received.
R1 RCM's Economic Impact: An Analysis
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: R1 RCM's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 15.6%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: R1 RCM's net margin is impressive, surpassing industry averages. With a net margin of 0.23%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): R1 RCM's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.05%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): R1 RCM's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.03%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: R1 RCM's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.66.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.